Navigation Links
Neurocrine Biosciences to Present at the 30th Annual J.P. Morgan Healthcare Conference
Date:1/6/2012

SAN DIEGO, Jan. 6, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 30th Annual J. P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco, California.   

The corporate presentation will review the Company accomplishments in 2011, as well as outline the corporate plans for 2012 and beyond.

Specifically, the Company will discuss the recent very productive Type C meeting that was held with the FDA on elagolix for endometriosis, one of the outcomes of which was the decision to file a Special Protocol Assessment (SPA) with the FDA. The expected NDA filing of elagolix for the treatment of endometriosis is in 2015.

Additionally, the presentation will cover the Company's VMAT2 program for movement disorders, including the status of the current Phase II study assessing the impact of NBI-98854 in patients with tardive dyskinesia. This study, which began in the fall of 2011, has recently completed enrollment and will report top-line data in the first quarter of 2012.  The Company also recently received a notification of allowable claims for its NBI-98854 European Patent Application from the European Patent Office, and has begun planning for larger Phase IIb trials, to be launched in mid-2012, for up to three months of continuous treatment with NBI-98854.

 

The live presentation takes place on Thursday, January 12, 2012 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time.  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.  A copy of the presentation materials will be filed with the Securities and Exchange Commission on or before Monday, January 9, 2012.

If you are unable to attend the webcast and would like further information on this announcement please contact Investor Relations at Neurocrine Biosciences at (858) 617-7600.  Viewers are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available approximately one hour after the conclusion of the live event and will be archived on the website for two weeks.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, stress-related disorders, tardive dyskinesia, uterine fibroids, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.

 


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Neurocrine Biosciences to Present at the 23rd Annual Piper Jaffray Health Care Conference
2. Neurocrine Biosciences to Present at the 2011 Credit Suisse Annual Health Care Conference
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2011 Financial Results
4. Neurocrine Biosciences Receives Second Milestone Payment of $20 Million Under Abbott Collaboration Agreement
5. Neurocrine Biosciences Announces Elagolix Scientific Presentations at the 67th Annual Meeting of the American Society for Reproductive Medicine
6. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
7. Neurocrine Biosciences Announces the Start of Phase II Study of Elagolix in Uterine Fibroids
8. Neurocrine Biosciences To Present at the Stifel Nicolaus 2011 Healthcare Conference
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2011 Financial Results
10. Neurocrine Biosciences Announces elagolix Scientific Presentations at the 11th World Congress on Endometriosis
11. Neurocrine Biosciences to Present at the Jefferies 2011 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Dec. 2, 2016 Lianluo Smart Limited ... "the Company") which develops, markets and sells medical ... China and international markets, recently ... and Treatment New Progress Forum, co-hosted by the ... Province , Guangdong Provincial People,s Hospital and ...
(Date:12/2/2016)... , December 2, 2016 On ... trading session in red, while the Dow Jones Industrial Average ... the close of US markets, which prompted Stock-callers this morning ... NuVasive Inc. (NASDAQ: NUVA ), Smith & Nephew ... NXTM ), and Cesca Therapeutics Inc. (NASDAQ: ...
(Date:12/2/2016)... , Dec 1, 2016 Research and ... "Drug Delivery in Cancer - Technologies, Markets and Companies" to ... , , ... in management of cancer The market value of drug ... market estimates from 2015-2025 are given according to organs involved and ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... FlexiSpot, a trusted name in ... trial program for all of the company’s desktop riser products. A simple application ... experience. , FlexiSpot’s unique desktop risers use an advanced dual gas spring hovering ...
(Date:12/2/2016)... ... , ... The annual time frame to change Medicare health and prescription drug ... 7th. Currently-enrolled Medicare beneficiaries who are looking to switch from their current plan to ... make changes during this period order for their new policy to go into effect ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... With the ... through rehabilitation of an injury, patients must find the one that works for them. ... pain, he created a machine that worked and decided to share it with others. ...
(Date:12/2/2016)... ... 02, 2016 , ... Dr. Raffi Hovsepian, a leading plastic, ... 2016 “Guide to America’s Top Plastic Surgeons” for seven consecutive years. The prestigious ... experience, and professional associations. , One the most frequently honored surgeons in ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... edition of "Cardiovascular Health" in USA Today, which covers the innovative treatments, therapeutic ... health while maintaining fulfilling lives. “We are prolonging life 6 years in the ...
Breaking Medicine News(10 mins):